Amgen to Invest $600 Million in California Headquarters for Science and Innovation Center

Amgen plans to invest $600 million in a new center for science and innovation at its California headquarters, expected to create hundreds of jobs and enhance collaboration among researchers, engineers, and scientists. The investment comes amid President Trump's threats to impose tariffs on pharmaceutical imports. The company has invested over $40 billion in manufacturing and R&D since the Tax Cuts and Jobs Act in 2017.

Amgen has announced plans to invest $600 million in a new state-of-the-art center for science and innovation at its headquarters in Thousand Oaks, California. The facility, expected to create hundreds of jobs, will enhance collaboration among researchers, engineers, and scientists, and is set to begin construction in the third quarter of 2025 [1].

This investment comes as President Trump has threatened to impose tariffs on pharmaceutical imports, which has prompted drugmakers to boost their presence in the U.S. Amgen's CEO, Bob Bradway, stated that the new center will empower scientists with advanced tools and a collaborative environment to drive scientific discovery and advance medicines [1].

The investment is part of Amgen's broader strategy to strengthen its research infrastructure and maintain a competitive edge in biotechnology. Since the passage of the Tax Cuts and Jobs Act in 2017, Amgen has invested over $40 billion in manufacturing and R&D, with $5 billion directed to U.S. capital expenditures [2]. This includes previous investments such as a $900 million expansion in Ohio and a $1 billion plant in North Carolina [2].

The new center will feature advanced automation and digital capabilities, addressing the need to accelerate discovery timelines through enhanced scientific collaboration and technology integration. This strategic investment is designed to leverage favorable tax policies and create a positive regional economic impact [2].

The construction of the facility is expected to commence in the third quarter of 2025, creating hundreds of jobs and contributing to Amgen's long-term research pipeline and growth prospects. The company's focus on cross-disciplinary collaboration and advanced automation underscores its commitment to developing complex biologic therapies [3].

References:
[1] https://www.cnbc.com/2025/09/02/amgen-investment-rd-facility-california.html
[2] https://www.stocktitan.net/news/AMGN/amgen-investing-more-than-half-a-billion-dollars-in-new-state-of-the-4ubb6mix6ufq.html
[3] https://www.marketwatch.com/story/amgen-to-invest-600-million-at-california-headquarters-77b5104b